All In Biotech

Drug Trial Radar · NCT03931928

Genotype and Phenotype Guided Supplementation of TAMoxifen Standard Therapy With ENDOXifen in Breast Cancer Patients

Genotype and Phenotype Guided Supplementation of TAMoxifen Standard Therapy With ENDOXifen in Breast Cancer Patients (TAMENDOX)

Last checked: Nov 19, 2026Latest source record: Sep 17, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 356 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

356

Actual

Start

Sep 10, 2019

Primary completion

May 3, 2021

Study completion May 3, 2021

Sponsor

Sponsor type
Academic, hospital or other
First posted
Apr 30, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

In hormone-receptor positive breast cancer or DCIS (ductal carcinoma in situ) tamoxifen remains an important treatment option for patients before menopause and those patients after menopause who cannot be treated with aromatase-inhibitors. Nonetheless, a considerable amount of patients suffer a relapse of their cancer while on treatment with tamoxifen. Tamoxifen is a drug that is metabolized to a variety of compounds by the human liver, and the most important antihormonally active metabolite is called (Z)-Endoxifen. It is known that patients who have a reduced or absent activity of the drug-metabolizing enzyme CYP2D6 have lower levels of (Z)-Endoxifen. Furthermore, it has been observed that patients on tamoxifen therapy who have absent CYP2D6 activity are at a 2-fold increased risk for disease recurrence, and patients with lower CYP2D6 compared to patients with normal CYP2D6 activity still have a 1.4-fold increased risk for disease recurrence. This trial will include patients who are already on tamoxifen therapy for at least 3 months and is designed to show that in patients with absent or low CYP2D6 activity, (Z)-Endoxifen supplementation - that is giving (Z)-Endoxifen in addition to tamoxifen for the study period of 42 days - can increase blood levels of (Z)-Endoxifen to therapeutic concentrations. It is planned to included 504 patients in this blinded, randomized trial, which will have a placebo group (receiving no (Z)-Endoxifen) and two intervention groups that will receive 0, 1.5 or 3 mg (Z)-Endoxifen depending on their CYP2D6 genetics or their (Z)-Endoxifen levels at the start of the study. The trial is not designed to evaluate outcome measures (that is recurrence or survival rates) of (Z)-Endoxifen supplementation in tamoxifen treated patients, but will document the safety of the combined administration of tamoxifen and (Z)-Endoxifen.

Conditions

  • Breast Cancer
  • DCIS

Interventions

  • (Z)-Endoxifen supplementation according to genotypeDrug

    Group 2: CYP2D6 genotype predicted intermediate metabolizer receive 1.5 mg, poor metabolizer receive 3 mg (Z)-Endoxifen and extensive or ultrarapid metabolizer receive 0 mg endoxifen (Placebo)

  • (Z)-Endoxifen supplementation according to plasma levelsDrug

    Group 3: Patients will receive (Z)-endoxifen according to (Z)-endoxifen steady state plasma concentrations (phenotype) at screening (i.e. ≤ 15 nM receive 3 mg, \> 15 and ≤ 25 nM receive 1.5 mg (Z)-Endoxifen and \> 25 nM receive 0 mg (Placebo)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. (Z-)endoxifen plasma concentration > 32 nMTime frame: 42 days (-2 days/+7 days)

Locations

40 sites in 1 country. Site status is shown where the registry gives one.

  • Gemeinschaftspraxis für Gynäkologie und Geburtshilfe Salzgitter

    Salzgitter, Albert-Schweitzer-Straße 18, Germany

  • Zentralklinikum Suhl, Klinik für Frauenheilkunde/Geburtsmedizin, Zentrum für klinische Studien

    Suhl, Albert-Schweitzer-Straße 2, Germany

  • Rems-Murr-Klinikum-Winnenden, Frauenklinik

    Winnenden, Am Jakobsweg 1, Germany

  • Robert-Bosch-Krankenhaus

    Stuttgart, Auerbachstr. 112, Germany

  • Onkologische Gemeinschaftspraxis Hildesheim, Gynäkologie

    Hildesheim, Bahnhofsplatz 5, Germany

  • Johanniter-Krankenhaus Stendal, Klinik für Frauenheilkunde und Geburtshilfe

    Stendal, Bahnhofstr. 24-26, Germany

  • Klinikum Magdeburg, Klinik für Hämatologie/Onkologie

    Magdeburg, Birkenallee 34, Germany

  • Klinikum Memmingen, Brustzentrum

    Memmingen, Bismarckstraße 23, Germany

  • Klinikum am Bruderwald Bamberg, Hämatologie/Internistische Onkologie

    Bamberg, Buger Straße 80, Germany

  • MVZ am Klinikum am Bruderwald Bamberg

    Bamberg, Buger Straße 80, Germany

  • Universitätsfrauenklinik Tübingen

    Tübingen, Calwer Straße 7, Germany

  • Helios Klinikum Gifhorn, Interdisziplinäres Brustzentrum

    Gifhorn, Campus 6, Germany

  • ViDiA Christliche Kliniken Karlsruhe, Frauenklinik

    Karlsruhe, Diakonissenstr.28, Germany

  • Klinikum Quedlinburg, Frauenklinik

    Quedlinburg, Ditfurter Weg 24, Germany

  • Klinikum Höchst Frankfurt am Main, Klinik für Gynäkologie und Geburtshilfe

    Frankfurt am Main, Gotenstr. 6-8, Germany

  • Evangelisches Diakonie-Krankenhaus Bremen, Frauenklinik

    Bremen, Gröpelinger Heerstraße 406-408, Germany

  • Onkologische Gemeinschaftspraxis Brudler-Heinrich-Bangerter Augsburg

    Augsburg, Halderstraße 29, Germany

  • medius Klinik Ostfildern-Ruit, Brustzentrum

    Ostfildern, Hedelfingerstraße 166, Germany

  • Helios Universitätsklinikum Wuppertal GmbH, Brustzentrum

    Wuppertal, Heusnerstraße 40, Germany

  • Klinikum Esslingen, Klinik für Frauenheilkunde, Brustzentrum

    Esslingen am Neckar, Hirschlandstraße 97, Germany

  • SRH Kliniken Sigmaringen, Gynäkologie und Geburtshilfe

    Sigmaringen, Hohenzollerstr. 40, Germany

  • Harz-Klinikum Wernigerode, Abteilung Gynäkologie und Geburtshilfe

    Wernigerode, Ilsenburger Straße 15, Germany

  • Klinikum Passau, Gynäkologische Onkologie

    Passau, Innstraße 76, Germany

  • St. Johannes Hospital Dortmund, Klinische Forschung

    Dortmund, Johannesstraße 9-17, Germany

  • Marienhospital Bottrop, Klinik für Gynäkologie und Geburtshilfe

    Bottrop, Josef-Albers-Straße 70, Germany

  • Universitätsfrauenklinik Mainz, Klinik und Poliklinik für Geburtshilfe und Frauenheilkunde

    Mainz, Langenbeckstr. 1, Germany

  • Onkozentrum Dresden, Fachärzte für Innere Medizin, Hämatologie und Internistische Onkologie

    Dresden, Leipziger Straße 120, Germany

  • HELIOS Dr. Horst Schmidt Kliniken Wiesbaden, Klinik für Gynäkologie und gyn. Onkologie

    Wiesbaden, Ludwig-Erhard-Straße 100, Germany

  • Luisenkrankenhaus Düsseldorf GmbH & Co. KG, Brustzentrum

    Düsseldorf, Luise-Rainer-Straße 6-10, Germany

  • Marienhospital Witten, Brustzentrum

    Witten, Marienplatz 2, Germany

  • Städtisches Klinikum Karlsruhe, Frauenklinik

    Karlsruhe, Moltkestr. 90, Germany

  • Kliniken der Stadt Köln, Brustzentrum Köln-Holweide

    Cologne, Neufelder Straße 32, Germany

  • Diakonissen-Krankenhaus Speyer, Klinik für Gynäkologie und Geburtshilfe

    Speyer, Paul-Egell-Straße 33, Germany

  • Klinikum Ludwigsburg, Frauenklinik

    Ludwigsburg, Posilipostraße 4, Germany

  • DRK Kliniken Berlin-Köpenick, Frauenklinik

    Köpenick, Salvador-Allende-Straße 2-8, Germany

  • MVZ Eggenfelden, Gynäkologische Onkologie

    Eggenfelden, Schellenbruckerstr. 15, Germany

  • Klinikum am Steinenberg Reutlingen, Frauenklinik

    Reutlingen, Steinenbergstr. 31, Germany

  • SRH Wald-Klinikum Gera GmbH, Klinik für Frauenheilkunde/Geburtsmedizin

    Gera, Straße Des Friedens 122, Germany

  • Elisabeth Krankenhaus Kassel gGmbH, Brustzentrum

    Kassel, Weinbergstr. 7, Germany

  • MVZ am Schlosssee Gifhorn

    Gifhorn, Zur Allerwelle 4, Germany

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.